Abstract
Of 695 patients who, in a five-year period, underwent cystectomy for bladder cancer, 32 (4.6 %) proved to have historical and pathologic Stage T1 (Stage A) transitional cell cancer. Of these, 23 (72 %) had grade 3 disease or higher. Overall, in 17 (53 %) progression developed after follow-up of ≥ 5 years. Moreover, in 10 (31 %) of the patients systemic progression developed during ten years. DNA ploidy pattern analysis did not prove helpful in predicting disease outcome. Because effective systemic chemotherapy has become available in the form of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin), it seems justifiable that patients who are considered to be candidates for cysteetomy because of high-grade, multifocal TI transitional cell cancer of the bladder also could be candidates for effective neo-adjuvant chemotherapy, in addition to those who usually are part of these protocols-namely, those with ≥ T2 disease.
| Original language | English |
|---|---|
| Pages (from-to) | 309-311 |
| Number of pages | 3 |
| Journal | Urology |
| Volume | 31 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1988 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Urology
Cite this
Radical cystectomy for historical and pathologic T1, N0, MO (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy? / Siref, Larry; Zincke, Horst.
In: Urology, Vol. 31, No. 4, 1988, p. 309-311.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Radical cystectomy for historical and pathologic T1, N0, MO (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy?
AU - Siref, Larry
AU - Zincke, Horst
PY - 1988
Y1 - 1988
N2 - Of 695 patients who, in a five-year period, underwent cystectomy for bladder cancer, 32 (4.6 %) proved to have historical and pathologic Stage T1 (Stage A) transitional cell cancer. Of these, 23 (72 %) had grade 3 disease or higher. Overall, in 17 (53 %) progression developed after follow-up of ≥ 5 years. Moreover, in 10 (31 %) of the patients systemic progression developed during ten years. DNA ploidy pattern analysis did not prove helpful in predicting disease outcome. Because effective systemic chemotherapy has become available in the form of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin), it seems justifiable that patients who are considered to be candidates for cysteetomy because of high-grade, multifocal TI transitional cell cancer of the bladder also could be candidates for effective neo-adjuvant chemotherapy, in addition to those who usually are part of these protocols-namely, those with ≥ T2 disease.
AB - Of 695 patients who, in a five-year period, underwent cystectomy for bladder cancer, 32 (4.6 %) proved to have historical and pathologic Stage T1 (Stage A) transitional cell cancer. Of these, 23 (72 %) had grade 3 disease or higher. Overall, in 17 (53 %) progression developed after follow-up of ≥ 5 years. Moreover, in 10 (31 %) of the patients systemic progression developed during ten years. DNA ploidy pattern analysis did not prove helpful in predicting disease outcome. Because effective systemic chemotherapy has become available in the form of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin), it seems justifiable that patients who are considered to be candidates for cysteetomy because of high-grade, multifocal TI transitional cell cancer of the bladder also could be candidates for effective neo-adjuvant chemotherapy, in addition to those who usually are part of these protocols-namely, those with ≥ T2 disease.
UR - http://www.scopus.com/inward/record.url?scp=0023939766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023939766&partnerID=8YFLogxK
U2 - 10.1016/0090-4295(88)90087-8
DO - 10.1016/0090-4295(88)90087-8
M3 - Article
VL - 31
SP - 309
EP - 311
JO - Urology
JF - Urology
SN - 0090-4295
IS - 4
ER -